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Background: We previously developed a bladder cancer-specific ligand (PLZ4) that can 
specifically bind to both human and dog bladder cancer cells in vitro and in vivo. We have 
also developed a micelle nanocarrier drug-delivery system. Here, we assessed whether the 
targeting micelles decorated with PLZ4 on the surface could specifically target dog bladder 
cancer cells.
Materials and methods: Micelle-building monomers (ie, telodendrimers) were synthesized 
through conjugation of polyethylene glycol with a cholic acid cluster at one end and PLZ4 at the 
other, which then self-assembled in an aqueous solution to form micelles. Dog bladder cancer 
cell lines were used for in vitro and in vivo drug delivery studies.
Results: Compared to nontargeting micelles, targeting PLZ4 micelles (23.2 ± 8.1 nm in diameter) 
loaded with the imaging agent DiD and the chemotherapeutic drug paclitaxel or daunorubicin 
were more efficient in targeted drug delivery and more effective in cell killing in vitro. PLZ4 
facilitated the uptake of micelles together with the cargo load into the target cells. We also 
developed an orthotopic invasive dog bladder cancer xenograft model in mice. In vivo studies 
with this model showed the targeting micelles were more efficient in targeted drug delivery than 
the free dye (14.3×; P , 0.01) and nontargeting micelles (1.5×; P , 0.05).
Conclusion: Targeting micelles decorated with PLZ4 can selectively target dog bladder can-
cer cells and potentially be developed as imaging and therapeutic agents in a clinical setting. 
Preclinical studies of targeting micelles can be performed in dogs with spontaneous bladder 
cancer before proceeding with studies using human patients.
Keywords: bladder urothelial carcinoma, nanoparticle, bladder cancer-specific peptide, targeted 
therapy, diagnostic imaging
Introduction
The prognosis and treatment of bladder cancer has not changed significantly over the 
last 30 years. Nanomedicine has recently been explored as a potential platform for 
developing anticancer strategies, ranging from prevention to early detection, imag-
ing/diagnosis, and therapy.1,2 Several nanotherapeutic agents such as Abraxane and 
Doxil have been approved, but their penetration ability is limited due to their rela-
tively large particle size (130 nm and 150 nm in diameter, respectively).3 To overcome 
the shortcomings of existing nanoformulations, Lou et al developed a novel micelle 
drug-delivery system.4,5 Telodendrimers, which are micelle-forming polymers, are 
composed of linear polyethylene glycol (PEG) conjugated with dendritic oligocholic 
acid (Figure 1A). Telodendrimers can self-assemble in an aqueous solution to form 
micelles that are characterized by their small size, long shelf life, and high efficiency 
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Figure 1 Characterization of targeting micelles. (A) The chemical structure of the telodendrimer. Dendritic oligomers of cholic acid are conjugated to the right ends of 
polyethylene glycol (PEG) while PLZ4 is at the left. The facial amphiphilic structure of cholic acid with the hydrophilic hydroxyl groups (red) at one side and hydrophobic 
methyl groups (blue) at the other side allows the formation of spheric micelles with PLZ4 displayed on the surface. (B) The spherical micelle structure with PLZ4 on the 
surface for targeting and the central space for loading of imaging and/or therapeutic agents. (C) Dynamic light scattering showing the size of targeting micelles (23.2 ± 8.1 nm) 
with narrow distribution. (D) Transmission electron microscopy imaging.
Note: Bar length is 50 nm.
in drug loading. PEG is biocompatible in that it has been 
extensively used in clinical settings, and cholic acid exists 
naturally in humans. Furthermore, these micelles are multi-
functional. Multiple imaging and therapeutic agents can be 
loaded and/or conjugated on the same micelles for various 
purposes. Smaller micelles (17–60 nm) also have better drug 
delivery to tumor sites compared to larger (.150 nm) ones.4 
Finally, cancer-targeting ligands can be conjugated to the 
distal end of PEG so they will be displayed on the surface of 
micelles to enhance drug delivery into the cancer cells.
We recently reported the development of PLZ4, a blad-
der cancer-targeting ligand from high throughput screening 
of combinatorial cyclic peptide libraries.6 It is the first such 
ligand that has high affinity and selectivity toward both 
human and dog urothelial cancer cell lines as well as cancer 
cells from clinical specimens.6,7 It does not bind to normal 
human or dog urothelial cells, blood cells, fibroblasts, 
human vascular endothelial cells, or other cell types. In 
vivo targeting/homing studies have shown that the binding 
of PLZ4 to bladder cancer xenografts is specific. In this 
study, we determined if PLZ4 enhances the tumor targeting 
of micelles to dog bladder cancer cells. If so, preclinical 
studies (including efficacy, pharmacology, and toxicology 
studies) can be performed in companion dog patients with 
spontaneous bladder cancer instead of the traditional but less 
 pathophysiologically-relevant mouse xenograft models.
Materials and methods
Synthesis and characterization of micelles
Both PLZ4 (amino acid sequence: cQDGRMGFc; upper-
case letters represent L-amino acids and lowercase letters 
represent unnatural D-cysteines used to cyclize and stabilize 
PLZ4) and telodendrimers were synthesized and character-
ized, including the chemical structure, purity, and cholic acid 
conjugation, as previously described (Figure 1A).4–6 In brief, 
the dendritic octamer of cholic acid was conjugated onto 
linear PEG via solution-phase condensation reactions. To 
synthesize targeting micelles in which 50% of the teloden-
drimers were conjugated to PLZ4, an aqueous-phase ‘click’ 
chemistry catalyzed by cuprous ions was used to couple 
the alkyne group on PLZ4 peptides to the azide group at 
the end of the PEG on the telodendrimer at a molar ratio 
of 1:2 (PLZ4:PEG).8 After conjugation, no free PLZ4 was 
detected, suggesting PLZ4 has been successfully conjugated 
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to the telodendrimer. The conjugation was further confirmed 
using proton nuclear magnetic resonance.1
To load daunorubicin (DNR), paclitaxel (PTX), or fluo-
rescent dye 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodica
rbocyanine (DiD) dye (Invitrogen, Carlsbad, CA), into the 
micelle, DNR/PTX/DiD (single reagent or a combination) 
and the telodendrimer (20 mg) were dissolved in chloroform 
(5 mL) in a 10-mL flask. The chloroform was removed using 
a rota-evaporator under vacuum. One mL of USP (United 
States Pharmacopeia) saline was then added into the flask. The 
mixture was vortexed and sonicated for 30 minutes at room 
temperature. The final product was analyzed for drug-loading 
capacity using high-performance liquid chromatography, 
micelle size and dispersion with a dynamic light scattering 
particle sizer, and transmission electron microscopy imag-
ing. It was filtered through a filter (0.22 µm) for sterilization 
and stored at 4°C for further studies. The maximal loading 
capacity was 5 mg/mL for DNR and 5–10 mg/mL for PTX in 
20 mg/mL of the telodendrimer. For the experiments presented 
here, the final concentration of DiD was 0.5 mg/mL, and the 
final concentrations of DNR and PTX were 1 mg/mL, with 
a telodendrimer concentration of 20 mg/mL. To synthesize 
targeting micelles, PLZ4-conjugated telodendrimers were 
used. After self-assembly, the more hydrophilic PLZ4 was 
displayed on the surface of the micelles for targeting.
Cell lines and culture condition
Three established and well-characterized dog invasive blad-
der urothelial cancer cell lines, including K9TCC, K9TCC-
Pu-In, and K9TCC-Pu-Axc, were used for this study.9 These 
cell lines were originally developed and directly provided by 
Dr Deborah Knapp of Purdue University in July, 2009. Cells 
were maintained in Dulbecco’s modified Eagle’s medium/
F12 (1:1) (Invitrogen) supplied with 10% fetal bovine serum 
and antibiotics. Normal primary dog urothelial cells were 
harvested from dogs euthanized for other unrelated reasons. 
A very thin layer of urothelial cells was scraped and washed 
with phosphate-buffered solution. The cells were then 
directly cultured on eight-chamber slides in the complete 
medium for 1–2 days before the experiment.
Fluorescence microscopy
To visualize the distribution of micelles in the cells, K9TCC-
Pu-In cells and normal dog urothelial cells were cultured in the 
eight-well chamber slides (BD Falcon, Franklin Lakes, NJ). 
The cells were then incubated with nontargeting micelles or 
targeting micelles with PLZ4 at 0.5 mg/mL telodendrimers 
in the complete medium. After incubation, the cells were 
washed to remove unbound micelles and covered with 
4′,6-diamidino-2-phenylindole (DAPI)-containing solution 
for nuclear staining (Sigma-Aldrich, St Louis, MO). The 
slides were then examined under an inverted fluorescence 
microscope. For high resolution cell imaging, K9TCC-Pu-
Axc cells were cultured on a glass-bottom culture dish (Mat-
Tek Corp, Ashland, MA) overnight. Micelles were diluted 
to 0.5 mg/mL telodendrimers in the complete medium and 
were incubated with micelles for 1 hour. After being lightly 
washed three times and fixed with 10% formalin for 20 min-
utes, the cells were stained with DAPI and examined. High-
resolution three-dimensional microscopy was performed 
using the DeltaVision system (Applied Precision, Issaquah, 
WA). Tomography images were taken and then deconvolved 
to determine the subcellular location of micelles with red 
fluorescence from DiD using a known optical transfer 
function and DeltaVision software algorithms, according to 
the manufacturer’s protocol.
Cell viability assay
K9TCC-Pu-In cells were seeded into 96-well plates at the 
final concentration of 10,000 cells per well in 100 µL of 
complete medium. The cells were incubated with various 
concentrations of nontargeting or targeting micelles loaded 
with DNR for 2 hours before being washed three times with 
phosphate-buffered solution and cultured with 100 µL of 
fresh complete medium for 72 hours at 37°C. The 2-hour 
incubation was used to mimic the in vivo clearance of 
micelles. Based on our pilot study, dog urothelial cancer 
cell lines appeared to be more resistant to PTX compared to 
human bladder cancer cell line 5637. Therefore, this study 
was performed with micelles loaded with DNR instead of 
PTX. Cell viability was assessed using the WST-8 prolifera-
tion assay (Cayman Chemical, Ann Arbor, MI) according to 
the manufacturer’s protocol.
Generation and characterization  
of an orthotopic mouse model  
of dog bladder cancer
All animal experiments were performed in compliance with 
institutional guidelines and according to protocols (No. 12988 
and No. 16065) approved by the Animal Use and Care 
 Administrative Advisory Committee of the University of 
California (Davis, CA). Thirteen 8-week-old male nonobese 
diabetic severe combined immunodeficient gamma mice were 
purchased from Jackson Laboratory (Indianapolis, IN) and 
used to generate the orthotopic model. The mice were anes-
thetized using an intraperitoneal injection of pentobarbital or 
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by isoflurane inhalation. The lower abdomen was prepared for 
surgery by proper scrubbing with an ethanol wipe. A small 
incision was performed at the bladder region and the bladder 
was isolated. K9TCC-Pu-In (105 cells in 10 µL phosphate-
buffered solution) was injected into the bladder wall with a 26 
G needle. A white focal spot stood for a successful injection 
procedure. After the injection, the abdomen was closed with 
the appropriate number of interrupted sutures, and the mice 
were monitored daily for wound healing, potential complica-
tions, body weight change, and tumor growth.
For histologic examination, the mice were sacrificed at 
days 1, 7, and 20 after injection. Whole bladders were har-
vested and fixed with 10% formalin. Tissue embedding and 
hematoxylin and eosin staining were done at the Veterinary 
Teaching Animal Hospital. Regarding the cytological evalua-
tion, the urine sediment smears and touch preparation smears 
were made and slides were stained with Hema3 (Fisher, 
Houston, TX). Imaging was performed using Metamorph 
microscopy automation and imaging analysis software 
(version 2.0; Molecular Devices, Silicon Valley, CA).
In vivo and ex vivo imaging of orthotopic 
xenograft dog bladder cancer in mice
The mice were injected with 100 µL of free DiD (0.5 mg/mL), 
nontargeting, or targeting micelles with PLZ4 on the surface, 
both loaded with DiD at 0.5 mg per 10 mg telodendrimer per 
mL with a total of 0.05 mg DiD per mouse. Three mice for 
each group in two independent experiments were used. The 
mice were put under anesthesia and the bladders were isolated 
outside the abdomen for in vivo imaging. Whole-body imag-
ing was performed and analyzed at 0, 2, 4, 8, and 24 hours 
using a Kodak multimodal-imaging system IS2000MM 
(Kodak, Rochester, NY). After the imaging, the mice were 
immediately euthanized. Whole bladders with tumors and 
other organs were harvested for ex vivo imaging. Imagines 
were further analyzed using IS2000MM software (Kodak).
Statistics
The experiments were repeated at least in triplicate. The mean 
values and standard deviations were determined for each set 
of experiments. For the determination of micelle delivery 
to tumor sites, we calculated mean fluorescence intensities 
of the tumor area and of the normal tissue area by means of 
the region-of-interest function using Kodak Image Analysis 
Software (Kodak). We then plotted a pseudocolored scale 
based on the semiquantitative information from near-infrared 
fluorescence images by integrating fluorescence intensities 
from equal areas within tumor and normal tissue regions. 
Student’s t-tests were used for statistics. A P value of less 
than 0.05 was considered significant.
Results
Characterization of drug-loaded targeting 
micelles decorated with PLZ4
We synthesized two types of micelles: the nontargeting 
micelles that did not have PLZ4 on the surface and target-
ing micelles that were decorated with PLZ4 on the surface 
( Figure 1B). Both types of micelles were loaded with 
the near-infrared imaging agent DiD and the therapeutic 
agent PTX or DNR. The median diameter of the micelles, 
with or without PLZ4 on the surface, was approximately 
23.2 ± 8.1 nm when loaded with PTX and DiD (Figure 1C). 
The spherical morphology and size of the micelles were con-
firmed by electronic microscopy (Figure 1D). The maximal 
drug loading capacity was 5 mg/mL for DNR and 10 mg/mL 
for PTX in 20 mg/mL of telodendrimer. Considering the 
doses of DNR and PTX at 45–60 mg/m2 and 175 mg/m2 in 
human patients, respectively, the anticipated blood level 
of the telodendrimer will be well below the toxic level of 
1 mg/mL observed in cell culture.5
Targeting micelles effectively delivered  
the cargo load into dog bladder  
cancer cells
To evaluate delivery efficiency, K9TCC-Pu-In (Figure 2A), 
K9TCC (Figure 2B), and K9TCC-Pu-Axc (Figure 2C) cells 
were incubated with micelles for 1 hour before washing. 
Both nontargeting and targeting micelles were able to deliver 
DiD to all these three cell lines in a dose-dependent manner. 
However, targeting micelles coated with PLZ4 exhibited 
significantly higher DiD. To further validate this finding, 
these cells were examined under a fluorescence microscope. 
K9TCC-Pu-In cells were treated with both nontargeting 
or targeting micelles loaded with DiD (50 µg/mL DiD in 
2 mg/mL telodendrimer). K9TCC-Pu-In took up more target-
ing micelles than nontargeting micelles. The uptake could 
be observed as early as 15 minutes after incubation (data not 
shown). No significant uptake of micelles by normal primary 
dog bladder urothelial cells was observed (Figure 3A). This 
data indicated the ability of dog bladder cancer cells to take 
up micelles even after a short period of incubation, and PLZ4 
on the micelle surface further improved the targeting and 
cell uptake of micelles. Furthermore, the targeting micelles 
could specifically deliver the drug load to cancer cells, but 
not to normal urothelial cells.
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Figure 2 More efficient delivery of targeting micelles into bladder cancer cell lines. (A) K9TCC-Pu-In, (B) K9TCC, and (C) K9TCC-Pu-Axc cells were incubated with various 
concentrations of nontargeting (NM) or targeting (PLZ4-NM) micelles, both loaded with DiD, for 1 hour before washing and analysis using an enzyme-linked immunosorbent 
assay reader.
Note: Targeting micelles were more efficient in drug delivery than nontargeting micelles in a dose-dependent pattern (*P , 0.05).
Abbreviation: DiD, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine.
To further determine whether PLZ4 functioned to 
attach micelles to the target cells or to induce the uptake of 
micelles, high-resolution tomography was performed using 
the DeltaVision system (Applied Precision) after cells were 
incubated with nontargeting or targeting micelles, both 
simultaneously loaded with DiD and PTX. After incuba-
tion for 1 hour, K9TCC-Pu-In cells were washed, fixed, 
and covered with DAPI-containing mounting medium for 
nuclear staining. As shown in Figure 3B, little uptake of DiD 
was observed when cells were incubated with nontargeting 
micelles. In contrast, when targeting micelles were incubated 
with cells, large amounts of red fluorescence were observed 
not only on cell surface and perinuclear areas, but also inside 
the nucleus as it overlapped with the DAPI (blue) nuclear 
s taining (Figure 3B, upper panel). These results were con-
sistent with several other reports showing preferential drug 
delivery with targeting nanoparticles.10,11 These results also 
support the notion that PLZ4 enhances nanoparticle attach-
ment to the cell surface and subsequent cell uptake.
PLZ4 enhanced the anticancer  
efficacy of drug-loaded micelles
To determine if the drug-loaded micelle formulation further 
increased antitumor efficacy, K9TCC-Pu-In cells were exposed 
to different concentrations of DNR-loaded nontargeting or 
targeting micelles. Consistent with our previous findings, empty 
micelles did not affect cell viability at any concentrations tested. 
DNR killed cancer cells in a dose-dependent manner, regardless 
of whether in the free form, nontargeting, or targeting micelle 
formulation. However, the targeting micelle formulation of 
DNR was more effective in cell killing than the free DNR or 
DNR loaded in the nontargeting micelles (Figure 4).
Establishment and characterization  
of an orthotopic dog bladder cancer  
xenograft model in mice
An orthotopic xenograft model would be essential to validate 
our micelle drug delivery system, as the location provides a 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2797
Targeting nanotherapeutics against bladder cancer
International Journal of Nanomedicine 2012:7
blood vessel system and supporting tissues that mirror the 
native cancer microenvironment. Here, we developed the 
orthotopic dog invasive bladder cancer xenograft model in 
mice through direct injection of K9TCC-Pu-In cells into the 
bladder wall. The mice tolerated the procedure well, with 
no significant complications. The tumor mass in the bladder 
became palpable approximately 2–3 weeks after injection. 
To further evaluate the growth of the orthotopic xenografts in 
the mouse bladder in detail, whole bladders were harvested 
at days 1, 7, and 20 after injection. Overall, the tumor uptake 
rate was 100% (13/13) based on pathological e xamination 
and tumor size ranged around 0.3–0.6 cm in diameter 
on day 20. Based on the histopathologic examination, tumor 
cells were mainly accumulated and limited in the lamina 
propria of the bladder on day 1 (Figure 5A and D). The 
cells were loosely clumped without organization or archi-
tecture. Rare cells were undergoing apoptosis ( Figure 5D). 
On day 7, the mass continuously expanded in the lamina 
propria and invaded the superficial layer of the muscularis 
propria.  Several nests of epithelial cancer cells with trabe-
cular  patterns s upported by abundant fibrovascular con-
nective tissues were seen (Figure 5B). The urothelial layer 
remained intact, and  inflammatory cells infiltrated the mass, 
especially in the peripheral areas (Figure 5E). On day 20 
(Figure 5C and F), the mass expanded in the lamina propria 
and extended into the bladder cavity, resulting in extreme 
limitation of urine storage ability. Tumor cells also further 
invaded through the full layer of the muscularis propria 
and into the surrounding fat tissues. The mitotic index was 
high. Rare areas of urothelium cells were necrotic and focal 
hemorrhage was noted.
Once the tumor cells penetrated through the urothelial 
layer, hematuria, and an increased number of nucleated 
cells in the urine were noted after a urine sediment smear 
evaluation. Figure 5G shows a small cluster of epithelial cells 
in the urine in a bloody background on day 20. Those atypi-
cal cells exhibited moderate anisocytosis and anisokaryosis, 
with round to irregular nuclei, stippled chromatin, multiple 
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Figure 3 Cell uptake of nontargeting and targeting micelles by dog bladder cancer cells. K9TCC-Pu-In cells were incubated with nontargeting (NM-DiD) or targeting 
micelles (PLZ4-NM-DiD), both loaded with DiD/PTX, for 1 hour before washing and imaging. (A) Comparison of cell uptake between nontargeting and targeting micelles 
with K9TCC-Pu-In (left) and normal dog primary urothelial cells (right) showing little retention of micelles with normal urothelial cells. The experiments were repeated three 
times with the cell line and twice with primary urothelial cells (100×). (B) High-resolution tomography showed the difference in the cell uptake of targeting (PLZ4-NM-DiD, 
upper panel) and nontargeting (NM-DiD, lower panel) micelles in K9TCC-Pu-Axc cells. 4′,6-diamidino-2-phenylindole (blue, nuclear staining) and white light phase images 
were presented to show nucleus and cell morphology, respectively.
Notes: The white arrow points to the attachment of targeting micelles to the cell membrane. Bar = 15 µm.
Abbreviations: DiD, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine; PTX, paclitaxel.
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nucleoli, and dark basophilic cytoplasm. Rare binucleated 
and multinucleated cells were seen. These cells resembled 
cells found on the bladder mass touch preparation slides and 
were diagnosed as cancer cells (Figure 5I). Rare cells con-
tained magenta amorphous materials in the cytoplasm and 
were interpreted as a secretory product (a common feature 
of urothelial cancer cytology in dogs).
In vivo micelle delivery to orthotopic  
dog bladder cancer xenografts in mice
After successful establishment of the orthotopic xenograft 
model, we determined if nontargeting and targeting micelles, 
both loaded with DiD and PTX, could have accumulated 
within the cancer xenografts. Both micelles were able to 
efficiently accumulate at the tumor site compared to the 
free DiD control group in vivo and ex vivo, suggesting 
that the so-called enhanced permeability and retention 
(EPR) mechanism played an important role in the delivery 
of micelles (Figure 6A–C). The targeting micelle group 
showed notably higher fluorescence signals at tumor sites 
compared to the free dye (14.3×; P , 0.01) or nontargeting 
group (1.5×; P , 0.05; Figure 6A–C). After normalizing 
tumor fluorescence with fluorescence in the liver, lungs, 
and muscles (Figure 6D), the results were generally consis-
tent with the in vivo imaging findings. In mice that did not 
undergo  orthotopic bladder cancer xenografting, no signal in 
the bladder was seen (data not shown), suggesting that only 
a limited number of DiD-loaded nontargeting or targeting 
micelles accumulated within normal bladder mucosa.
To further evaluate the distribution of micelles, fresh 
frozen slides were prepared and stained for CD31, a marker 
for vascular endothelial cells (Supplementary material 1). 
No signals were observed in the group treated with DiD. In 
contrast, both groups treated with nontargeting or targeting 
micelles exhibited patches of fluorescence signals with vari-
able sizes. Xenografts from the mice treated with targeting 
micelles appeared to have higher signals than the nontarget-
ing group. This finding was consistent with the in vivo and 
ex vivo imaging results stated above. In addition, blood ves-
sels (CD31 positive) were scattered throughout the tumors, 
mainly in the fibrovascular-supporting tissues in all three 
groups, indicating that the difference was not from the vari-
ance in blood vessel distribution. The distribution of DiD 
was not homogenous inside the tumor, as evidenced by the 
variably sized signal patches, suggesting that delivery of 
DiD to tumor sites was not secondary to blood circulation 
and simple diffusion.
Discussion
This is the first report on the development of bladder cancer-
targeting nanoparticles that can potentially improve the 
imaging detection and treatment of bladder cancer. This 
project combined a bladder cancer-targeting ligand, PLZ4, 
with a novel micelle drug delivery system. When decorated 
with PLZ4 on the surface, targeting micelles could not only 
adhere to the dog bladder cancer cell surface, but were also 
taken up into the target cancer cells. In vivo studies showed 
that the targeting micelles were more efficient in delivering 
the therapeutic and imaging agents into the orthotopic blad-
der cancer xenografts. Given the great similarities between 
human and dog bladder cancers, this will allow all of the 
preclinical studies (to human patients) to be performed in 
dogs with spontaneous bladder cancer before clinical trials 
in human patients.
The unique advantage of the micelle system is that 
 multiple imaging and therapeutic agents can be conjugated to 
telodendrimers or loaded in micelles (Figure 1A). When dec-
orated with PLZ4, these imaging agents can be specifically 
delivered to the cancer sites. Targeted delivery of imaging 
agents has already been used in clinical settings. For example, 
an octreoscan combines the diethylene triamene penta-acetate 
conjugate of octreotide with the imaging agent radioisotope 
Indium-111, and has been used for imaging detection of 
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Figure 4 Cell cytotoxicity assay of drug-loaded micelles on dog bladder cancer. 
K9TCC-Pu-In cells were seeded and cultured overnight before being treated 
with various concentrations of nontargeting or targeting micelles loaded with 
daunorubicin (DNR) for two hours at 37°C. Cells treated with empty micelles and 
free DNR under the same conditions served as controls. Cells were then washed 
and cultured with complete culture medium for 72 hours and the cell viability was 
evaluated using the WST-8 assay according to the manufacturer’s protocol. The 
absorbance was detected using an enzyme-linked immunosorbent assay reader. This 
experiment was performed in triplicate and repeated three times.
Notes: *P = 0.02 for free DNR versus PLZ4 micelles and 0.04 for free DNR versus 
nontargeting micelles. **P = 0.001 for free DNR versus PLZ4 micelles; 0.01 for 
free DNR versus nontargeting micelles; and 0.04 for nontargeting versus targeting 
micelles.
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neuroendocrine tumors bearing somatostatin receptors.12 We 
have previously shown that PLZ4 directly conjugated to a 
near-infrared fluorescent dye Cy5.5 concentrated in the tumor 
xenograft sites in mouse models developed from human clini-
cal bladder cancer specimens and from dog bladder cancer 
cell lines.6,7 No significant accumulation in other organs, 
including the native bladder, was observed except that both 
PLZ4-Cy5.5 and the control dye Cy5.5 also concentrated in 
the kidneys, possibly secondary to nonspecific renal trapping. 
Here, we showed that targeting PLZ4 micelles loaded with 
the imaging agent DiD also concentrated in the bladder in 
the tumor xenografts (Figure 6). However, we did see some 
uptake of micelles in the liver and lungs. However, the fluo-
rescence in the tumor xenografts was much stronger. It has 
also been shown that the nonspecific uptake of micelles by 
normal organs could be significantly reduced using micelles 
with a slight negative charge on the surface.13 Together, 
these data suggest that targeting micelles can potentially be 
developed as a more efficient, noninvasive, real-time imag-
ing diagnostic tool.
The targeting micelle decorated with PLZ4 can also be 
used for therapeutic purposes. Both nontargeting and targeting 
micelles concentrated within tumor xenografts, suggesting 
the enhanced EPR of nanoparticles.14 However, conjugation 
of PLZ4 on the surface of micelles not only contributed to 
the attachment of micelles to target cancer cell surfaces, but 
also induced the uptake of micelles by cancer cells (Figure 3). 
Furthermore, PLZ4 enhanced targeted delivery of micelles to 
the orthotopic bladder cancer xenografts (Figure 6).
This micelle drug delivery system can potentially 
improve the treatment outcomes of bladder cancer through 
four possible mechanisms. First, micelles can enhance drug 
delivery to the tumor sites through the EPR effect.14 EPR 
is achieved at the “leaky” neovasculature secondary to the 
disorganized and poorly aligned vascular endothelial cells 
at the tumor sites.15 We have shown that the EPR effect was 
size- dependent. More EPR effects were observed with small 
micelles (20–60 nm) compared to nanoparticles of approxi-
mately 150 nm.4 Compared to the FDA-approved Abraxane 
and Doxil (130 nm and 150 nm in diameter, respectively), 
our drug-loaded micelles are typically small (23.2 ± 8.1 nm, 
in this case. See Figure 1).
Second, tumor-targeting ligands can further enhance 
the antitumor activity of nanoparticles.16 To enhance the 
Day 1 Day 7
A B C
D E
G H
F
Day 20
Figure 5 Establishment of dog orthotopic bladder cancer xenograft model in mice. Whole bladders were harvested on days 1 (A and D), 7 (B and E), and 20 (C and F) 
after injection of cancer cells for hematoxylin and eosin staining and examination. Blue arrows show an intact normal urothelial layer lining the bladder cavity on day 1 and 
replacement of the normal urothelial layer and bladder cavity by xenograft on day 20. Blue stars show the injection (day 1) and expansion of cancer cells (day 7) at the lamina 
propria and invasion into the muscle layer on day 20. (A, B and C: 4×; D, E, and F: 40×). (G) urine sediment cytology evaluation on day 20 (40×). (H) The touch preparation 
smear from the solid tumor in the bladder at day 20 (40×).
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antitumor activity of the nanoformulation, various targeting 
ligands have been studied, such as arginine-glycine-aspartic 
acid-containing peptides,17 transferrin,18,19 antibody or single-
chain variable fragments,20 and several others. These cancer-
targeting ligands could potentially enhance the antitumor 
efficacy of the nanoparticles by actively seeking and deliv-
ering nanoparticles to the cancer sites,21,22 or by introducing 
the nanoparticles into cancer cells.23–25 Here, we showed that 
PLZ4-decorated micelles possess both features of targeting 
nanoparticles (Figures 3 and 6).
Third, a synergistic effect can be achieved by load-
ing multiple anticancer agents in the same micelles. 
Furthermore, a radioisotope can be conjugated to achieve 
concurrent chemoradiation, and imaging probes can be loaded 
for the in vivo real-time monitoring of drug delivery. To date, 
more than a dozen drugs have been successfully loaded into 
micelles. In this project, we loaded the micelles with both thera-
peutic PTX and optical imaging DiD. In addition, other bio-
logic compounds, such as DNA and RNA, can potentially be 
loaded. We found that small noncoding regulatory microRNA 
might be involved in the chemoresistance of bladder cancer.26 
Therefore, the simultaneous delivery of therapeutic agents 
and chemotherapy sensitizers into cancer cells may be able to 
improve the treatment outcomes of bladder cancer.
50 700 1200 2500
DiD PLZ4-NM-DiDNM-DiD
A
Lung
Heart
Liver
Spleen
Intestine
Bladder
/K9TCC-Pu-In
Kidney
Muscle
DiD PLZ4-NM-DiDNM-DiDB
Tumor/liver Tumor/lung
0.0
0.5
1.0
1.5
2.0
2.5
*
* *
R
at
io
DiD
NM-DiD
PLZ4-NM-DiD
0
2
4
6
8
10 *
*
R
at
io
Tumor/muscle
DC
DiD
NM
-D
iD
PL
Z4
-N
M-
DiD
0
1000
2000
3000
*
* *
F
lu
o
re
sc
en
ce
s
Figure 6 In vivo and ex vivo imaging on an orthotopic dog invasive bladder cancer model in mice. (A) In vivo imaging of mice 24 hours after receiving free DiD dye or 
nontargeting (NM-DiD) or targeting (PLZ4-NM-DiD) micelles loaded with PTX/DiD. Mice were covered to protect bladder xenografts and to prevent evaporation of vital 
organs. (B) Ex vivo imaging of the tumor/bladder and other major organs 24 hours after injection. The color bar represents the relative fluorescence strength. (C) The 
average fluorescence strength of whole tumor/bladder for free DiD, NM-DiD, and PLZ4-NM-DiD was calculated from three different mice (*P , 0.05). (D) To eliminate 
other variations, the fluorescence signals of xenografts were normalized with the signals of the liver, lungs, and muscles of the same mice (*P , 0.05).
Abbreviations: DiD, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicar bocyanine; PTX, paclitaxel.
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Fourth, the formulation of chemotherapeutic drugs in 
micelles can decrease toxicity. This is especially true with 
PTX as it is not very water soluble and needs a special solvent 
composed of Cremophor® EL (polyoxyethylated castor oil) 
and dehydrated alcohol. This solvent can cause severe aller-
gic reactions and requires corticosteroid and antihistamine 
premedications. We have previously found that PTX in the 
micelle formulation at three times the therapeutic dose had 
a similar toxicity to the parental PTX in mouse models, but 
with vastly superior therapeutic effects.4
The dog orthotopic xenograft model developed for this 
study closely resembles human invasive bladder cancer 
stage T2 (invading the muscularis propria) and stage T3 
(extending to tissue outside the bladder) and thus serves as a 
great model for both diagnostic imaging and targeted therapy 
for this disease. Several other bladder cancer models have 
been developed. However, those models resemble superficial 
bladder cancer.27,28
Our findings suggest that PLZ4 micelles can potentially 
be developed for diagnostic and therapeutic applications in 
dog bladder urothelial carcinoma. Dog bladder cancer is a 
clinical challenge in terms of early diagnosis and treatment. 
It is the most common bladder cancer in dogs and accounts 
for over 85% of urinary tract neoplasms.29 Current treat-
ment has not been very successful due to the nature of 
cancer invasiveness, high metastasis rates (37%–50% at 
diagnosis), and poor responses to chemotherapy.30,31 Even 
with a multimodal combination of chemotherapy, surgery, 
and radiotherapy, the prognosis is poor. Therefore, a better 
and more specific targeting carrier system may be helpful 
for disease management.
In summary, we have presented a novel multifunctional 
targeting micelle delivery system that can potentially be 
developed for imaging and therapeutic applications in dog 
bladder cancer. Considering the great similarity between 
dog and human bladder cancer, and that PLZ4 also binds to 
human bladder cancer cells, the PLZ4 micelle system has 
the potential for human applications. Based on this study, a 
Phase I clinical trial is currently being developed to deter-
mine the efficacy and toxicity of paclitaxel-loaded targeting 
micelles in dog patients with spontaneous bladder cancer.
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Figure S1 Intratumoral distribution of micelles. After ex vivo imaging of tumor xenografts, cryosections (10 µm thick) were obtained and the samples were fixed with 
10% formalin for 10 minutes at room temperature. After 30 minutes of blocking in 1% BSA/PBS, samples were incubated with 1:100 antiCD31 (blood vessel endothelium 
cell marker) antibody (Millipore, Billerica, MA) for 1 hour at room temperature. Goat antimouse IgG conjugated Cy3 was used as a secondary antibody for another 1 hour 
at room temperature. Before observing using the microscope, slides were mounted using DAPI-containing antifading mounting medium. The imaging was acquired using 
Metamorph Microscopy Automation and Imaging analysis software (Molecular Devices). The distribution of DiD/micelles is shown as red, while the vascular endothelial 
marker CD31 is shown as yellow and the nucleus/DAPI as blue in the xenografts from mice treated with free DiD (upper panel), nontargeting micelles (NM-DiD, middle 
panel), and PLZ4-targeting micelles (PLZ4-NM-DiD, lower panel). The very right panel shows the merged imaging.
Abbreviations: BSA/PBS, bovine serum albumin/phosphate-buffered solution; DAPI, 4′,6-diamidino-2-phenylindole; DiD, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicar 
bocyanine.
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